Paroxysmal Atrial Fibrillation: Insight Into the Intimate Mechanisms of Coagulation

Negreva, Мariya; Ana, Zarkova; Prodanova, Krasimira; Petrov, Petar

doi:10.14740/cr972

Cited by 7 publications

(8 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies here are also controversial [25][26][27]. Our results showed significant activation of coagulation [14][15][16][17]. The statistical analysis showed no significant difference between the patient and the control group in terms of age and sex demographics, as well as in accompanying diseases and treatment, deleterious habits and BMI (p> 0.05) (Table 4).…”

Section: Discussionmentioning

confidence: 57%

“…At the same time, this could complement and expand the established embolic risk assessment scale for AFthe CHA2DS2-VASc score. Our previous studies showed that the clinical manifestation of PAF is associated with very early activation of the coagulation process [14][15][16][17]. We found that as early as the first twenty-four hours of the disease there was a significant increase in plasma coagulation activity of factor II (FII, p <0.001), factor V (FV, p <0.001), factor VII (FVII, p <0.001), factor FVIII (FVIII, p <0.001), factor IX (FIX, p <0.001), factor X (FX, p <0.001), factor XI (FXI, p <0.001), factor XII (FXII, p <0.001), vWF activity (p <0.001), as well as plasma levels of tissue factor (TF, p <0.001), FVIII (p <0.05), vWF (p <0.001), prothrombin fragment 1+2 (F1 + 2, p <0.001) and fibrinopeptide A (FPA, p <0.001) in the studied patient population, compared to controls without prior arrhythmic data.…”

Section: Introductionmentioning

confidence: 99%

“…In patients, the blood sample was taken immediately after diagnosis in still persistent disease, and in controls during a conducted outpatient examination. The preparation, storage and examination of samples is duly described elsewhere [14][15][16][17].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Mathematical Models for the Prediction of Coagulation Activity in Patients with Paroxysmal Atrial Fibrillation

Prodanova¹,

informatics²,

Negreva³

2020

IJBSAC

Self Cite

View full text Add to dashboard Cite

Our previous studies showed activation of coagulation in the early hours of the clinical manifestation of paroxysmal atrial fibrillation (PAF). Plasma coagulation activity of factor II, factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, vWF, tissue factor levels, FVIII, vWF, prothrombin fragment 1+2(F1 + 2) and fibrinopeptide A (FPA) were significantly increased as early as the first twenty-four hours of the disease. The results suggest that there is a correlation between the studied parameters and development of the disease. Aim: To search for a statistical model that predicts coagulation activity in PAF patients. Materials and methods: Coagulation parameters were examined in 51 PAF patients (26 males, 25 females; mean age 59.84 ±1.60 years, onset of PAF episode < 24h prior to hospitalization). Controls included 52 individuals (26 males, 26 females; mean age 59.50 ± 1.46 years) with no prior anamnestic or ECG AF data, corresponding to patients in sex, age, BMI and comorbidities. A linear regression model was used to predict coagulation activity in PAF. Regression models showed good correlation between the duration of arrhythmia and six of the fourteen coagulation parameters studied: F1+2 (r = 0.83, p <0.001), FPA (r = 0.84, p <0.001), FVIII levels (r = 0.85, p <0.001) as well as activity of FII (r = 0.83, p <0.001), FVIII (r = 0.83, p <0.001) and FXII (r = 0.78, p <0.001). Changes in F1+2 plasma levels were most sensitive to PAF duration, where the contribution of duration to the values of the indicator is the greatest (b = 15.31). Conclusion: Linear regression analysis allowed us to create models with a high correlation coefficient for predicting the values of F1+2, FPA, FVIII levels, as well as activity of FII, FVIII and FXII in PAF patients. These models could allow for quantification of the procoagulatory process and thrombotic potential of the disease.

show abstract

Section: Discussionmentioning

confidence: 57%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Mathematical Models for the Prediction of Coagulation Activity in Patients with Paroxysmal Atrial Fibrillation

Prodanova¹,

informatics²,

Negreva³

2020

IJBSAC

Self Cite

View full text Add to dashboard Cite

show abstract

“…AF is a hypercoagulable state. Through bioinformatics analysis in the previous stage, compared with the CON group, HBG1 and HBD were significantly increased in the AF group, while HBG1 and HBD were the main molecules involved in oxygen transport, and HBG1 and HBD had a significant protein interaction with factor Xa, resulting in a significant difference in coagulation function between the AF group and the CON group; Mariya Negreva et al found that paroxysmal AF tends to have an early hypercoagulable state, involving intrinsic and extrinsic coagulation pathways in their study (Negreva et al, 2020). Rivaroxaban is a commonly used clinical anticoagulant.…”

Section: Discussionmentioning

confidence: 84%

Beneficial Effect of Edoxaban on Preventing Atrial Fibrillation and Coagulation by Reducing Inflammation via HBG1/HBD Biomarkers

et al. 2022

View full text Add to dashboard Cite

Background: Atrial fibrillation (AF) is the most common cardiac arrhythmia. The effectiveness and mechanism of edoxaban in preventing stroke after atrial fibrillation remain unclear.Methods: The expressions of HBG1 and HBD in red blood cells were tested in AF. Sixty C57B/6J mice were randomly divided into the following groups: the control (CON) group, atrial fibrillation (AF) group, AF + edoxaban group, and AF + rivaroxaban group. H&E staining assay and reticular fiber staining were performed. Myocardial fibrosis was evaluated by the Masson staining assay, Sirius red staining assay, and immunohistochemical assay for the expressions of α-SMA and COL1A1. ELISA and RT-PCR assay were performed for the detection of inflammatory parameters (TNF-α, IL-1β, IL-6, and IL-10). Blood lipids were detected by using the Beckman automatic biochemical analyzer. Furthermore, four items of coagulation were detected, and molecular docking among HBG1, HBD, and MASP1 (Xa) was performed by PyMOL 2.1 software. The BP neural network model, cubic spline interpolation, and support vector machine model were constructed to predict prothrombin time based on HBG1 and HBD expressions. COIP assay was performed to construct the interaction between HBG1 and HBD. The functional enrichment analysis was performed by DAVID and Metascape tools.Results: The expressions of HBG1 and HBD in red blood cells of the patients with atrial fibrillation were decreased. The results showed a lower level of hemoglobin in red blood cells with HBG1-siRNA and HBG1-siRNA. Compared with the AF group, the collagen fiber percentage in the AF + edoxaban group was decreased (p < 0.05). After using edoxaban, the expressions of TNF-α, IL-1β, IL-6, and IL-10 were significantly decreased (p < 0.05). The LDL-C, TC, and TG levels were downregulated in the AF + edoxaban group. The PT and APTT levels in the AF + edoxaban group were more increasing than in the AF mice (p < 0.05). Compared with the AF group, the expressions of HBG1 and HBD were downregulated in the AF + edoxaban group (p < 0.05). HBG1 protein matched well with HBD and MASP1(Xa) protein surfaces. There exists a significant interaction between HBG1, HBD, and PT via the BP neural network and support vector machine. Enrichment analysis showed that HBG1 and HBD were mainly enriched in blood coagulation.Conclusion: Edoxaban could prevent atrial fibrillation and coagulation by reducing inflammation, lipids, and fibrosis via HBG1/HBD biomarkers effectively, and the effect was superior to that of rivaroxaban.

show abstract

“…Тому виникнення розладів кровотоку в лівому передсерді підвищує ризик серцево-емболічних подій з утворенням тромбу та зміною показників гомеостазу із залученням внутрішніх і зовнішніх шляхів коагуляції. Доведено, що в пацієнтів із ФП спостерігається підвищений рівень показників коагуляційної активності, таких як D-димер, фібриноген, антитромбін III (ATIII), комплекс тромбін-антитромбін III, фрагментів протромбіну, що сприяє посиленню гемокоагуляції [18][19][20]. Небезпека ФП для пацієнта пов'язана з виникненням серйозних ускладнень: порушенням гемодинаміки з розвитком серцевої недостатності та тромбоемболій.…”

Section: вступunclassified

Клініко-Функціональні Та Психоемоційні Закономірності Перебігу Постійної Й Пароксизмальної Форми Фібриляції Передсердь

Serediuk¹,

Vakalyuk²

2022

TPJ

View full text Add to dashboard Cite

Метою дослідження є аналіз динаміки клініко-функціональних та психоемоційних показників у хворих із постійною і пароксизмальною формою фібриляції передсердь. Матеріали та методи. У дослідження залучно 64 хворих із постійною і пароксизмальною формою фібриляції передсердь (ФП), поділених на підгрупи, залежно від методу лікування. Для оцінки перебігу ФП проводили інструментальні і психометричні методи дослідження стану серцево-судинної системи. Результати. Встановлено, що додавання анксіолітичного препарату до стандарту лікування у хворих із постійною формою ФП інтенсивніше усуває прояви прискореного серцебиття, задишки в спокої, виражену втому, пітливість. Крім того, виявлено позитивний ефект лікування на електрокардіографічні та ехокардіографічні параметри серця, що підтверджено статистично. У процесі лікування бальний показник стресу і депресивної симптоматики достовірно знижувався в обох групах хворих. Схожа тенденція спостерігалася у хворих із пароксизмальною формою ФП із достовірною різницею показників до лікування, після лікування і через 1,5 місяця. Висновок. Таким чином, додаткове призначення анксіолітичного засобу у хворих із постійною і пароксизмальною формою ФП сприяло зниженню показників клінічної симптоматики ФП, регресу гіпертрофії лівого шлуночка, покращувало процеси внутрішньошлуночкової провідності, а також збільшувало фракцію викиду лівого шлуночка, сприяло інтенсивному бальному зниженню рівня стресу (p2<0,001) та його редукції з високого до низького рівня, а також бальному зниженню показників депресії (p2<0,001).

show abstract

Paroxysmal Atrial Fibrillation: Insight Into the Intimate Mechanisms of Coagulation

Cited by 7 publications

References 34 publications

Mathematical Models for the Prediction of Coagulation Activity in Patients with Paroxysmal Atrial Fibrillation

Mathematical Models for the Prediction of Coagulation Activity in Patients with Paroxysmal Atrial Fibrillation

Beneficial Effect of Edoxaban on Preventing Atrial Fibrillation and Coagulation by Reducing Inflammation via HBG1/HBD Biomarkers

Клініко-Функціональні Та Психоемоційні Закономірності Перебігу Постійної Й Пароксизмальної Форми Фібриляції Передсердь

Contact Info

Product

Resources

About